Actively Recruiting
Compassionate Use Study of Diffusing Alpha Radiation Therapy DaRT for Treating Malignant Tumors
Led by Alpha Tau Medical LTD. · Updated on 2026-06-16
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the compassionate use of Diffusing Alpha Radiation Therapy DaRT for treating malignant tumors in patients who cannot participate in other investigational trials. The study primarily focuses on assessing the frequency, severity, and cause of acute side effects related to DaRT treatment. Additionally, it evaluates tumor response three months after DaRT seed insertion using standard tumor measurement criteria. Participants receive DaRT seeds inserted directly into the tumor following planned radiotherapy guidelines. The placement is checked by volumetric imaging 2 to 3 weeks after insertion, and the seeds are then removed. This open-label, single-group study collects data on safety and efficacy in patients with tumors up to 7 centimeters and life expectancy longer than six months. During the study, participants will be monitored for acute adverse events from the time of DaRT insertion. Tumor response will be assessed three months later. Women of childbearing potential must have a negative pregnancy test and use contraception for three months post-treatment. Overall participation lasts until tumor response assessment and safety data collection are complete, with ongoing monitoring of side effects throughout the study period.
CONDITIONS
Brief Title
Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors
Research Team
L
Liron Dimnik
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here